BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Varela M, Sala M, Llovet JM, Bruix J. Natural history and prognostic prediction of patients with hepatocellular carcinoma: REVIEW: NATURAL HISTORY AND PROGNOSTIC PREDICTION. Alimentary Pharmacology & Therapeutics 2003;17:98-102. [DOI: 10.1046/j.1365-2036.17.s2.11.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y, Ikeda F, Shiraha H, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K. Evolution of prognostic factors in hepatocellular carcinoma in Japan. Alimentary Pharmacology & Therapeutics 2010;31:407-14. [DOI: 10.1111/j.1365-2036.2009.04179.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
2 Dhanasekaran R, Khanna V, Kooby DA, Spivey JR, Parekh S, Knechtle SJ, Carew JD, Kauh JS, Kim HS. The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2010;21:1197-204. [DOI: 10.1016/j.jvir.2010.04.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hiotis SP, Rahbari NN, Villanueva GA, Klegar E, Luan W, Wang Q, Yee HT. Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol. 2012;12:64. [PMID: 22681852 DOI: 10.1186/1471-230x-12-64] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
4 Allen J, Venook A. Hepatocellular carcinoma: epidemic and treatment. Curr Oncol Rep 2004;6:177-83. [PMID: 15066228 DOI: 10.1007/s11912-004-0047-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
5 Couto OFM, Dvorchik I, Carr BI. Causes of Death in Patients with Unresectable Hepatocellular Carcinoma. Dig Dis Sci 2007;52:3285-9. [DOI: 10.1007/s10620-007-9750-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
6 Liu TC, Vachharajani N, Chapman WC, Brunt EM. SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases. Am J Surg Pathol 2014;38:966-72. [PMID: 24805857 DOI: 10.1097/PAS.0000000000000218] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
7 Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Takayama H, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol. 2011;26:1195-1200. [PMID: 21410750 DOI: 10.1111/j.1440-1746.2011.06720.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
8 Huo T, Wu J, Lin H, Lee F, Hou M, Huang Y, Lee P, Chang F, Lee S. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. Liver Transpl 2004;10:1507-13. [DOI: 10.1002/lt.20310] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
9 Cabibbo G, Genco C, Di Marco V, Barbara M, Enea M, Parisi P, Brancatelli G, Romano P, Craxì A, Cammà C. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation: Predicting survival after TACE for hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2011;34:196-204. [DOI: 10.1111/j.1365-2036.2011.04694.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
10 Romanque P, Piguet AC, Dufour JF. Targeting vessels to treat hepatocellular carcinoma. Clin Sci (Lond). 2008;114:467-477. [PMID: 18302534 DOI: 10.1042/CS20070310] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 Liu PH, Lee YH, Hsu CY, Huang YH, Chiou YY, Lin HC, Huo TI. Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within the Milan criteria. Ann Surg Oncol. 2014;21:3835-3843. [PMID: 24903236 DOI: 10.1245/s10434-014-3831-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
12 Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci. 2008;53:2359-2365. [PMID: 18273705 DOI: 10.1007/s10620-007-0175-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
13 Huo TI, Lee PC, Huang YH, Wu JC, Lin HC, Chiang JH, Lee SD. The sequential changes of the model for end-stage liver disease score correlate with the severity of liver cirrhosis in patients with hepatocellular carcinoma undergoing locoregional therapy. J Clin Gastroenterol 2006;40:543-50. [PMID: 16825938 DOI: 10.1097/00004836-200607000-00014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
14 Tang GE, Niu YX, Li Y, Wu CY, Wang XY, Zhang J. Paris saponin VII enhanced the sensitivity of HepG2/ADR cells to ADR via modulation of PI3K/AKT/MAPK signaling pathway. Kaohsiung J Med Sci 2020;36:98-106. [PMID: 31688993 DOI: 10.1002/kjm2.12145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]